Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer -

Trial Profile

Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer -

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2013 Recruitment complete, according to the Iranian Registry of Clinical Trials.
    • 25 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top